13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839948
Total reported value
$4.2B
$4.2B
38 檔
7.9%
As reported in its official Q4 2024 Form 13F filing, TCG Crossover Management, LLC's tracked investment portfolio stood at $4.2B with 38 total positions.
In Q4 2024, TCG Crossover Management, LLC displayed an active expansion posture, initiating 5 new positions and adding to 4 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 10.29% | -0.84% | — | |
| 2 | DYN | Dyne Therapeutics Inc | Stock-Other | 6.10% | +0.07% | — | |
| 3 | XNCR | Xencor Inc | Stock-Other | 5.51% | +0.10% | +1.03% | |
| 4 | COGT | Cogent Biosciences Inc | Stock-Other | 5.31% | -0.93% | — | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.73% | -4.87% | EXIT | |
| 6 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.44% | -0.01% | — | |
| 7 | UPB | Upstream Bio Inc | Stock-Other | 4.38% | -0.05% | EXIT | |
| 8 | ABVX | Abivax Sa-adr | Stock-Other | 4.33% | -1.41% | — | |
| 9 | SVRA | Savara Inc | Stock-Other | 3.71% | -0.10% | — | |
| 10 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.24% | +0.52% | — | |
| 11 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.20% | -0.10% | — | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 3.02% | -0.09% | — | |
| 13 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.97% | — | — | |
| 14 | TRML | Tourmaline Bio Inc | Stock-Other | 2.93% | — | — | |
| 15 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.82% | -0.19% | EXIT | |
| 16 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.70% | -1.07% | — | |
| 17 | EYPT | Eyepoint Inc | Stock-Other | 2.60% | — | +287.31% | |
| 18 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.55% | — | — | |
| 19 | ✓ | Third Harmonic Bio Inc | Stock-Other | 2.52% | — | +3.74% | |
| 20 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.42% | — | — | |
| 21 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.41% | — | — | |
| 22 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 2.41% | -1.15% | EXIT | |
| 23 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 2.04% | +0.34% | — | |
| 24 | ✓ | Rapt Therapeutics Inc | Stock-Other | 1.93% | — | — | |
| 25 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.72% | +0.22% | — | |
| 26 | CMPS | Compass Pathways PLC | Stock-Other | 1.43% | — | — | |
| 27 | KURA | Kura Oncology Inc | Stock-Other | 1.21% | — | — | |
| 28 | MBX | Mbx Biosciences Inc | Stock-Other | 1.17% | +0.30% | — | |
| 29 | KOD | Kodiak Sciences Inc | Stock-Other | 1.11% | -0.23% | +13.63% | |
| 30 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.99% | -0.64% | — | |
| 31 | KROS | Keros Therapeutics Inc | Stock-Other | 0.85% | — | -37.45% | |
| 32 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.82% | — | -10.55% | |
| 33 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.77% | -0.04% | EXIT | |
| 34 | ✓ | Stock-Other | 0.58% | — | — | ||
| 35 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.36% | — | — | |
| 36 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.35% | +1.02% | — | |
| 37 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.07% | — | — | |
| 38 | CABA | Cabaletta Bio Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UPB | Upstream Bio Inc | +4.4% | NEW | New buy |
| 2 | TNGX | Tango Therapeutics Inc | +3.2% | NEW | New buy |
| 3 | DNTH | Dianthus Therapeutics Inc | +3.2% | NEW | New buy |
| 4 | CDTX | Cidara Therapeutics Inc | +2.6% | NEW | New buy |
| 5 | EYPT | Eyepoint Inc | +2% | +287.31% | Add |
| 6 | ✓ | Rapt Therapeutics Inc | +1.9% | NEW | New buy |
| 7 | XNCR | Xencor Inc | +1.4% | +1.03% | Add |
| 8 | IRON | Disc Medicine Inc | +1% | — | Unchanged |
| 9 | KOD | Kodiak Sciences Inc | +0.9% | +13.63% | Add |
| 10 | FULC | Fulcrum Therapeutics Inc | +0.8% | — | Unchanged |
| 11 | 260 | Centessa Pharmaceuticals-adr | +0.8% | — | Unchanged |
| 12 | OCUL | Ocular Therapeutix Inc | +0.5% | — | Unchanged |
| 13 | AMLX | Amylyx Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 14 | MLYS | Mineralys Therapeutics Inc | +0.4% | — | Unchanged |
| 15 | TRDA | Entrada Therapeutics Inc | +0.2% | — | Unchanged |
| 16 | ✓ | +0.2% | — | Unchanged | |
| 17 | VTGN | Vistagen Therapeutics Inc | +0.1% | — | Unchanged |
| 18 | SLNOEUR | Soleno Therapeutics Inc | +0.1% | — | Unchanged |
| 19 | VTYXUSD | Ventyx Biosciences Inc | 0% | — | Unchanged |
| 20 | CABA | Cabaletta Bio Inc | 0% | — | Unchanged |
| 21 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
| 22 | NKTREUR | Nektar Therapeutics | -0.1% | — | Unchanged |
| 23 | ANTX | An2 Therapeutics Inc | -0.1% | EXIT | Sold out |
| 24 | CATBUSD | Astria Therapeutics Inc | -0.2% | — | Unchanged |
| 25 | ✓ | Third Harmonic Bio Inc | -0.3% | +3.74% | Add |
| 26 | MBX | Mbx Biosciences Inc | -0.3% | — | Unchanged |
| 27 | TRML | Tourmaline Bio Inc | -0.3% | — | Unchanged |
| 28 | AVU0 | Adverum Biotechnologies Inc | -0.4% | -10.55% | Trim |
| 29 | CMPS | Compass Pathways PLC | -0.6% | — | Unchanged |
| 30 | TARS | Tarsus Pharmaceuticals Inc | -0.7% | EXIT | Sold out |
| 31 | SVRA | Savara Inc | -0.7% | — | Unchanged |
| 32 | COGT | Cogent Biosciences Inc | -1.1% | — | Unchanged |
| 33 | GPCR | Structure Therapeutics Inc | -1.1% | — | Unchanged |
| 34 | KURA | Kura Oncology Inc | -1.2% | — | Unchanged |
| 35 | TYRA | Tyra Biosciences Inc | -1.3% | — | Unchanged |
| 36 | CGON | Cg Oncology Inc | -1.4% | — | Unchanged |
| 37 | ABVX | Abivax Sa-adr | -1.6% | — | Unchanged |
| 38 | DYN | Dyne Therapeutics Inc | -2% | — | Unchanged |
| 39 | SLN | Silence Therapeutics Plc-adr | -2.6% | — | Unchanged |
| 40 | KROS | Keros Therapeutics Inc | -3.5% | -37.45% | Trim |
| 41 | EWTX | Edgewise Therapeutics Inc | -4.8% | EXIT | Sold out |
According to official SEC Form 13F filings, TCG Crossover Management, LLC reported a total U.S. public equity portfolio value of $4.2B across 38 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, DYN, XNCR) accounted for 7.9% of total reported equity market value during Q4 2024.
Top New Position Initiated
UPB
市值: $44.9M
Top Position Liquidated / Trimmed
EWTX
前期市值: $56.4M
During Q4 2024, TCG Crossover Management, LLC's top holdings by market value included CGON (10.3%)、DYN (6.1%)、XNCR (5.5%). The largest single position, CGON, represented 10.3% of total portfolio value.
In Q4 2024, TCG Crossover Management, LLC made 14 total portfolio adjustments, initiating 5 new buys, adding to 4 positions, trimming 2 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.